Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2010 2
2013 1
2015 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
[Update on Current Care Guideline: Diabetic retinopathy].
Summanen P, Kallioniemi V, Komulainen J, Eriksson L, Forsvik H, Hietala K, Tulokas S, Von Wendt G; Päivitystiivistelmä. Summanen P, et al. Among authors: kallioniemi v. Duodecim. 2015;131(9):893-4. Duodecim. 2015. PMID: 26237887 Finnish.
Diabeettinen retinopatia.
Summanen P, Kallioniemi V, Komulainen J, Lamminen H, Levänen H, Orhanen E, Tulokas S, Virtamo T, von Wendt G. Summanen P, et al. Among authors: kallioniemi v. Duodecim. 2007;123(4):421-2. Duodecim. 2007. PMID: 17405707 Finnish. No abstract available.
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA; ACCOMPLISH Trial investigators. Bakris GL, et al. Lancet. 2010 Apr 3;375(9721):1173-81. doi: 10.1016/S0140-6736(09)62100-0. Epub 2010 Feb 18. Lancet. 2010. PMID: 20170948 Clinical Trial.
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S; LEAD-1 SU study group. Marre M, et al. Diabet Med. 2009 Mar;26(3):268-78. doi: 10.1111/j.1464-5491.2009.02666.x. Diabet Med. 2009. PMID: 19317822 Free PMC article. Clinical Trial.